| Interacting proteins: Q9UJM3 and P04626 |
Pubmed |
SVM Score :0.0 |
| The product of rat gene 33 was identified as an ErbB 2 interacting protein in a two hybrid screen employing the ErbB 2 juxtamembrane and kinase domains as bait . ^^^ Activation of ErbB 2 catalytic function was required for ErbB 2 gene 33 physical interaction in living cells , whereas ErbB 2 autophosphorylation was dispensable . ^^^ Expression of gene 33 protein was absent in growth arrested NIH 3T3 fibroblasts but was induced within 60 to 90 min of serum stimulation or activation of the ErbB 2 kinase and decreased sharply upon entry into S phase . ^^^ New differentiation factor stimulation of mitogen deprived mammary epithelial cells also caused accumulation of gene 33 protein , which could be found in a complex with ErbB 2 . ^^^ Overexpression of gene 33 protein in mouse fibroblasts inhibited ( 1 ) cell proliferation driven by ErbB 2 but not by serum , ( 2 ) cell transformation induced by ErbB 2 but not by Ras or Src , and ( 3 ) sustained activation of ERK 1 and 2 by ErbB 2 but not by serum . ^^^ |
|
| Interacting proteins: Q9UJM3 and P04626 |
Pubmed |
SVM Score :0.0 |
| Over expression studies have demonstrated that RALT ( receptor associated late transducer ) is a feedback inhibitor of ErbB 2 mitogenic and transforming signals . ^^^ Here , we show that physiological levels of RALT effectively suppress ErbB 2 mitogenic signals . ^^^ |
|
| Interacting proteins: Q9UJM3 and P04626 |
Pubmed |
SVM Score :0.0 |
| The ErbB 2 interacting protein receptor associated late transducer ( RALT ) was previously identified as a feedback inhibitor of ErbB 2 mitogenic signals . ^^^ We now report that RALT binds to ligand activated epidermal growth factor receptor ( EGFR ) , ErbB 4 and ErbB 2 . ^^^ Remarkably , RALT deltaEBR retained the ability to suppress largely the proliferative activity of ErbB 2 . ^^^ ErbB 3 dimers over a wide range of ligand concentrations , indicating that RALT can intercept ErbB 2 . ^^^ |
|
| Interacting proteins: Q9UJM3 and P04626 |
Pubmed |
SVM Score :0.0 |
| Loss of RALT / MIG 6 expression in ERBB 2 amplified breast carcinomas enhances ErbB 2 oncogenic potency and favors resistance to Herceptin . ^^^ Although mutational inactivation of the RALT gene was not detected in human breast carcinomas , RALT mRNA and protein expression was strongly and selectively reduced in ERBB 2 amplified breast cancer cell lines . ^^^ Reconstitution of RALT expression in ERBB 2 amplified SKBr 3 and BT 474 cells inhibited ErbB 2 dependent mitogenic signalling and counteracted the ability of ErbB ligands to promote resistance to the ErbB 2 targeting drug Herceptin . ^^^ Thus , loss of RALT expression cooperates with ERBB 2 gene amplification to drive full oncogenic signalling by the ErbB 2 receptor . ^^^ Moreover , loss of RALT signalling may adversely affect tumor responses to ErbB 2 targeting agents . . ^^^ |
|